Yesterday, the Regenexbio Inc (NASDAQ: RGNX) stock emerged as one of the notable gainers in the premarket trading period after the company made a key announcement.
The stock surged by 5.50% during premarket trading after the company made an announcement with regards to its product RGX 121. Regenexbio announced that it successfully provided the first dose to a patient as part of the Cohort 3 of the Phase I/III clinical trial of the product. The product is meant for treating patients who might be suffering from Hunter Syndrome.
It is a significant development for the company and the surge in the stock during the premarket trading period did not come as a complete surprise. Steve Pakola, who is the Chief Medical Officer of the company, stated that Regenexbio is pleased with the kind of progress that has been made with regards to RGX 121 so far. It now remains to be seen if the stock remains in action this morning.
Editor and Computer Expert
A hardcore tech enthusiast and computer expert Uson Abdilazhanov who holds a degree in communications started writing in his personal blogs since 2012. That time he was interested in the technical part of the computer. But now the software aspect plays an important role in his career. Currently, he runs a PC building and repairing shop which helps a lot of designers and gamers who always like to try new things.